Biotech Investors Howling At Yellen After Federal Reserve Report Roils Sector
This article was originally published in RPM Report
Executive Summary
“Equity valuations” for biotech companies “appear to be stretched,” the Federal Reserve cautions. Biotech investors and analysts disagree.